

Amendment

The listing of claims will replace all prior versions, and listings, of claims in the application.

Listing of Claims

1. (Previously presented) An oligopeptide having the amino acid sequence:
Arg-nL-nL-nL-Arg-nL-nL-nL-Gly-Tyr (SEQ ID NO:13).
2. (Previously presented) The oligopeptide according to Claim 1 wherein one or more of the amino acids of said oligopeptide are D isomers.
3. (Previously presented) The oligopeptide according to Claim 2, wherein all the amino acids of said oligopeptide, other than glycine, are D isomers.
4. (Previously presented) The oligopeptide according to Claim 1, wherein the terminal carboxyl group of said oligopeptide is amidated.
5. (Previously presented) The oligopeptide according to Claim 1, wherein said oligopeptide is in salt form.
6. (Previously presented) The oligopeptide according to Claim 1, wherein the terminal carboxyl group of said oligopeptide is the acetate salt of an amide.
7. (Original) An oligopeptide having the structural formula:
H-(D)Arg-(D)nL-(D)nL-(D)nL-(D)Arg-(D)nL-(D)nL-(D)nL-Gly-(D)Tyr-NH₂.
8. (Currently Amended) ~~An A-pharmaceutical composition comprising an oligopeptide according to any one of Claims 1 to 7 and a pharmaceutically acceptable medium.~~ Claim 7, where said oligopeptide is in salt form.
9. (Canceled)
10. (Canceled)

11. **(Previously presented)** The oligopeptide according to Claim 2, wherein the terminal carboxyl group of said oligopeptide is amidated.
12. **(Previously presented)** The oligopeptide according to Claim 3, wherein the terminal carboxyl group of said oligopeptide is amidated.
13. **(Previously presented)** The oligopeptide according to Claim 2, wherein said oligopeptide is in salt form.
14. **(Previously presented)** The oligopeptide according to Claim 3, wherein said oligopeptide is in salt form.
15. **(Previously presented)** The oligopeptide according to Claim 4, wherein said oligopeptide is in salt form.
16. **(Canceled)**
17. **(Canceled)**
18. **(Previously presented)** The oligopeptide according to Claim 2, wherein the terminal carboxyl group of said oligopeptide is the acetate salt of an amide.
19. **(Previously presented)** The oligopeptide according to Claim 3, wherein the terminal carboxyl group of said oligopeptide is the acetate salt of an amide.
20. **(Previously presented)** The oligopeptide according to Claim 4, wherein the terminal carboxyl group of said oligopeptide is the acetate salt of an amide.
21. **(Previously presented)** The oligopeptide according to Claim 5, wherein the terminal carboxyl group of said oligopeptide is the acetate salt of an amide.
- 22-28. **(Canceled)**

Serial No.: 10/780,321
Filing Date: February 17, 2004

29. **(Currently Amended)** A pharmaceutical composition comprising an oligopeptide ~~according to any one of Claims 11 to 28~~ as in any of Claims 1-8 or Claims 11-15 or Claims 18-21, further comprising ~~and~~ a pharmaceutically acceptable medium.

30. **(Previously presented)** The pharmaceutical composition according to Claim 29, wherein said pharmaceutically acceptable medium comprises an excipient.

31. **(Previously presented)** The pharmaceutical composition according to Claim 30, wherein said excipient comprises mannitol.